Empowering CAR-T cells to conquer solid tumors through synergistic expansion and persistence.
Contact Us
Platform Overview
Despite remarkable success in hematologic malignancies, CAR-T therapies face critical challenges in solid tumors, including limited T cell trafficking, poor intratumoral infiltration, and rapid exhaustion. To address these bottlenecks, Protheragen proudly presents our innovative EnhanceCAR™ platform. This next-generation technology is specifically engineered to activate CAR-T cells in a novel, antigen-independent manner, driving robust expansion and potent cytotoxicity against hard-to-treat solid tumors, as demonstrated in proof-of-concept studies for colorectal and prostate cancers.
Disruptive Technology
Excellent Team
Diversified Pipeline
Customized Solutions
Platform Core
The EnhanceCAR™ platform utilizes a dual-signal design. Unlike conventional CARs that rely solely on TCR-like signaling via the target antigen, EnhanceCAR™ introduces a proprietary "boost signal." This signal promotes CAR-T cell expansion through co-stimulatory and cytokine pathways, bypassing the need for abundant antigen engagement. This mechanism enhances T cell proliferation, shifts them toward a memory-like phenotype with reduced exhaustion, and facilitates superior tumor infiltration. The typical workflow of the EnhanceCAR™ platform is outlined below:
Platform Advantages
Superior In Vivo Expansion
Our platform drives CAR-T cell expansion exceeding 100-fold in patients, ensuring high therapeutic cell doses without requiring complex manufacturing modifications. This remarkable expansion is achieved through a proprietary dual-signal mechanism that activates CAR-T cells via co-stimulatory and cytokine pathways, bypassing the need for abundant antigen engagement and simplifying the manufacturing process compared to conventional approaches.
Enhanced Tumor Trafficking & Infiltration
EnhanceCAR™ cells demonstrate improved homing to tumor sites, overcoming a major barrier in solid tumor immunotherapy. Unlike conventional CAR-T cells that often fail to adequately penetrate the tumor microenvironment, EnhanceCAR™-engineered cells exhibit enhanced chemotaxis and adhesion properties, ensuring a greater proportion of the expanded cell population reaches both primary lesions and metastatic deposits.
Exhaustion Resistance
By promoting a memory-like T cell phenotype, the platform maintains CAR-T cell fitness and effector function for longer durations within the suppressive tumor microenvironment. While conventional CAR-T cells rapidly upregulate exhaustion markers upon persistent antigen stimulation, EnhanceCAR™-engineered cells retain their proliferative capacity and cytotoxic potency, translating into sustained tumor control and reduced relapse rates.
Platform Application
Target antigens like GCC to treat late-stage, refractory colorectal cancer. Demonstrated robust clinical responses with manageable safety profiles.
Utilize targets such as PAP or PSMA to treat metastatic castration-resistant prostate cancer (mCRPC), showing potent anti-tumor activity in preclinical and early clinical models.
The platform’s modular design allows for rapid adaptation to other antigens, making it applicable for pancreatic, ovarian, or triple-negative breast cancer.
EnhanceCAR™ cells serve as an ideal backbone for combining with checkpoint inhibitors or oncolytic viruses, potentially unlocking synergistic effects in "cold" tumors.
Pipeline
| Projects | Target | Indication | Discovery | Preclinical | IND | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|---|---|
| SYN005 | GCC | Colorectal Cancer | ||||||
| SYN009 | PAP | Prostate Cancer | ||||||
| SYN014 | PSMA | Prostate Cancer | ||||||
| SYN018 | TSHR | Thyroid Cancer | ||||||
| SYN023 | Undisclosed | Pancreatic Cancer | ||||||
| SYN029 | Undisclosed | Autoimmune Diseases | ||||||
Contact Us
FAQs
Q1: How is EnhanceCAR™ different from conventional CAR-T for solid tumors?
Q2: Has this platform shown clinical responses in patients?
Q3: What types of targets can be adapted to the EnhanceCAR™ platform?
Q4: What is the safety profile of EnhanceCAR™?
Q5: What is the success rate of generating high-quality EnhanceCAR™ batches?
The EnhanceCAR™ platform empowers CAR-T cells with enhanced expansion, tumor infiltration, and exhaustion resistance for effective solid tumor therapy.
Copyright © 2026 Protheragen. All rights reserves.